Briefing: Pharma Delays Launches in Europe Amid U.S. Pressure
Strategic angle: Drugmakers are postponing the release of new medicines in Europe due to shifting pricing policies and pressures from the U.S.
Editorial Staff
1 min read
Updated 4 months ago
Pharmaceutical companies are facing challenges in launching new drugs in Europe.
The delays are attributed to U.S. pricing policy changes.
Notable deals include those involving Lilly and Biogen.